These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 32315682)
1. Peri-strut low intensity areas and in-scaffold neointima growth after bioresorbable scaffold implantation in STEMI. A serial optical coherence tomography study. Ochijewicz D; Tomaniak M; Kołtowski L; Rdzanek A; Pietrasik A; Proniewska K; Partyka L; Dijsktra J; Huczek Z; Filipiak K; Opolski G; Kochman J Int J Cardiol; 2020 Aug; 312():27-32. PubMed ID: 32315682 [TBL] [Abstract][Full Text] [Related]
2. Relationship between peri-strut low intensity areas and vascular healing response after everolimus-eluting bioresorbable scaffold implantation: An optical coherence tomography study. Sato T; Jose J; El-Mawardy M; Sulimov DS; Tölg R; Richardt G; Abdel-Wahab M J Cardiol; 2017 Apr; 69(4):606-612. PubMed ID: 27520757 [TBL] [Abstract][Full Text] [Related]
3. Serial Baseline, 12-, 24-, and 60-Month Optical Coherence Tomography Evaluation of ST Segment Elevation Myocardial Infarction Patients Treated with Absorb Bioresorbable Vascular Scaffold. Koltowski L; Tomaniak M; Ochijewicz D; Zieliński K; Proniewska K; Malinowski KP; Zaleska M; Maksym J; Roleder T; Partyka L; Kochman W; Filipiak KJ; Opolski G; Kochman J Am J Cardiol; 2021 Sep; 155():23-31. PubMed ID: 34315572 [TBL] [Abstract][Full Text] [Related]
4. Third-Generation Sirolimus-Eluting Bioresorbable Tyrocore Scaffold Implantation in Patients with ST-Segment Elevation Myocardial Infarction: Baseline and 6-Month OCT and Clinical Outcomes-a FANTOM STEMI Pilot Study. Koltowski L; Tomaniak M; Ochijewicz D; Opolski G; Kochman J Cardiovasc Drugs Ther; 2024 Aug; 38(4):719-729. PubMed ID: 36640215 [TBL] [Abstract][Full Text] [Related]
5. First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation Absorb bioresorbable vascular scaffold. Kochman J; Kołtowski Ł; Tomaniak M; Jąkała J; Proniewska K; Legutko J; Roleder T; Piertrasik A; Rdzanek A; Kochman W; Brugaletta S; Opolski G; Regar E EuroIntervention; 2018 Apr; 13(18):e2201-e2209. PubMed ID: 29155384 [TBL] [Abstract][Full Text] [Related]
6. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy. Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079 [TBL] [Abstract][Full Text] [Related]
7. Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study. Toušek P; Kočka V; Malý M; Lisa L; Buděšínský T; Widimský P Heart Vessels; 2016 Jun; 31(6):841-5. PubMed ID: 25896128 [TBL] [Abstract][Full Text] [Related]
8. A 12-month angiographic and optical coherence tomography follow-up after bioresorbable vascular scaffold implantation in patients with ST-segment elevation myocardial infarction. Kochman J; Tomaniak M; Kołtowski Ł; Jąkała J; Proniewska K; Legutko J; Roleder T; Pietrasik A; Rdzanek A; Kochman W; Brugaletta S; Kaluza GL Catheter Cardiovasc Interv; 2015 Oct; 86(4):E180-9. PubMed ID: 26015294 [TBL] [Abstract][Full Text] [Related]
9. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study. Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the peri-strut low intensity area following sirolimus- and paclitaxel-eluting stents implantation: insights from an optical coherence tomography study in humans. Otake H; Shite J; Ikeno F; Shinke T; Teramoto T; Miyoshi N; Ako J; Honda Y; Fitzgerald PJ; Hirata K Int J Cardiol; 2012 May; 157(1):38-42. PubMed ID: 21168926 [TBL] [Abstract][Full Text] [Related]
11. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164 [TBL] [Abstract][Full Text] [Related]
12. Comparison of post-stent irregular protrusion and subsequent neointimal characteristics between second- and third-generation drug-eluting stent implantation. Miura T; Sonoda S; Sanuki Y; Naka Y; Okabe H; Setoyama K; Inoue K; Shimizu A; Anai R; Tsuda Y; Araki M; Otsuji Y J Cardiol; 2020 Nov; 76(5):464-471. PubMed ID: 32636130 [TBL] [Abstract][Full Text] [Related]
13. Bioresorbable scaffold implantation in STEMI patients: 5 years imaging subanalysis of PRAGUE-19 study. Kočka V; Toušek P; Kozel M; Buono A; Hajšl M; Lisa L; Buděšínský T; Malý M; Widimský P J Transl Med; 2020 Jan; 18(1):33. PubMed ID: 32000796 [TBL] [Abstract][Full Text] [Related]